Skip to content
value.today

Perspective Therapeutics, Inc.

CATX
$141 Mmarket cap on Oct 30, 2026
Compare
World rank
#17,501
Revenue
—
For year ending December-2025
Net income
$-103 M
SEC filing
Employees
—

Perspective Therapeutics, Inc. in brief

Perspective Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $141 M on 30 October 2026, which makes it the 17,501st largest listed company in the world and the 3,335th largest in the USA on this site. Its shares trade under the symbol CATX (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Perspective Therapeutics, Inc.

We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

From the company's annual report filed with the US SEC: read the report

Perspective Therapeutics, Inc. timeline

3 events, 1995–2023
  1. 1995
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2005
  4. ✎
    Renamed IsoRay, Inc.
    Formerly Century Park Pictures Corp.
  5. 2023
  6. ✎
    Renamed Perspective Therapeutics, Inc.
    Formerly IsoRay, Inc..

Events of Perspective Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$82 M$164 M$246 M$329 M

World rank over time

▼ down 2,737 places since 2026
2026-10-13: #14800#14,80020262026-10-30: #17537#17,5372026

Rank in USA: #2,861 (Oct 2026) · #3,339 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.7×
Free cash flow yield
-67.4%
Net margin
—
Operating margin
—
Return on equity
-49.8%
Liabilities / assets
22.5%
Net debt
$-29M
Revenue growth
-85.8%
R&D / revenue
1490.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2018: revenue $6M, net income $-7M$6MFY18Fiscal year ending Jun 2019: revenue $7M, net income $-5M$7MFY19Fiscal year ending Jun 2020: revenue $10M, net income $-3M$10MFY20Fiscal year ending Jun 2021: revenue $10M, net income $-3M$10MFY21Fiscal year ending Dec 2022: revenue —, net income $-11M—FY22Fiscal year ending Dec 2023: revenue $1M, net income $-47M$1MFY23Fiscal year ending Dec 2024: revenue —, net income $-79M—FY24Fiscal year ending Dec 2025: revenue —, net income $-103M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-114M$-103M—
Dec 2024——$-91M$-79M—
Dec 2023$1M—$-41M$-47M-3252.4%
Dec 2022——$-9M$-11M—
Jun 2021$10M+3.8%$-3M$-3M-33.7%
Jun 2020$10M+32.4%$-3M$-3M-35.6%
Jun 2019$7M+23.5%$-5M$-5M-70.3%
Jun 2018$6M—$-7M$-7M-113.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-82M$13M$-95M$-1.40—
Dec 2024$-18M$54M$-73M$-1.23—
Dec 2023$-37M$1M$-38M$-1.74—
Dec 2022$-10M$0M$-11M——
Jun 2021$-3M$0M$-3M$-0.03—
Jun 2020$-4M$0M$-4M$-0.05—
Jun 2019$-5M$0M$-5M$-0.08—
Jun 2018$-6M$0M$-6M$-0.12—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-40M—Dec ’24Three months to Mar 2025: revenue —, net income $-18M—Mar ’25Three months to Jun 2025: revenue —, net income $-21M—Jun ’25Three months to Sep 2025: revenue —, net income $-26M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-37M—Dec ’25Three months to Mar 2026: revenue —, net income $-26M—Mar ’26Three months to Jun 2026: revenue —, net income $-27M—Jun ’26Three months to Sep 2026: revenue —, net income $-32M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Perspective Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-114 M
Net income
$-103 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$267 M
Total liabilities
$60 M
Total equity
$207 M

As of December-2025

Top 100 institutional investors in Perspective Therapeutics, Inc.#

As of Sep 30, 2026
118 institutions held 79.9 M shares (about 66.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 44.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Perspective Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.11,827,346+2,333,194 (+24.58%)9.79%$33 MNov 13, 2026
2TCG Crossover Management, LLC7,915,5670 (0.00%)6.55%$22 MNov 16, 2026
3Millennium Management LLC6,193,174+1,281,319 (+26.09%)5.13%$17 MNov 16, 2026
4Avidity Partners Management LP6,067,999-232,000 (-3.68%)5.02%$17 MNov 16, 2026
5Vanguard Capital Management LLC4,407,246-29,326 (-0.66%)3.65%$12 MNov 13, 2026
6Affinity Asset Advisors, LLC3,988,744-225,838 (-5.36%)3.30%$11 MNov 13, 2026
7Citadel Advisors LLC3,978,908+173,169 (+4.55%)3.29%$11 MNov 16, 2026
8Spruce Street Capital LP3,693,9310 (0.00%)3.06%$10 MNov 13, 2026
9Two Sigma Investments, LP2,993,831+1,437,380 (+92.35%)2.48%$8 MNov 16, 2026
10ADAR1 Capital Management, LLC2,617,870+1,407,753 (+116.33%)2.17%$7 MNov 16, 2026
11Nantahala Capital Management, LLC2,492,642-2,158,258 (-46.41%)2.06%$7 MNov 13, 2026
12Geode Capital Management, LLC2,037,352-421,321 (-17.14%)1.69%$6 MNov 6, 2026
13State Street Corp2,026,991-4,024,780 (-66.51%)1.68%$6 MNov 12, 2026
14Nicholson Wealth Management Group, LLC1,618,993-1,000 (-0.06%)1.34%$4 MNov 9, 2026
15Marshall Wace, LLP1,481,991New1.23%$4 MNov 13, 2026
16UBS Group AG1,262,215+817,298 (+183.70%)1.05%$3 MNov 10, 2026
17Dimensional Fund Advisors LP1,227,846+153,775 (+14.32%)1.02%$3 MNov 4, 2026
18Yu Fan1,055,4090 (0.00%)0.87%$3 MNov 16, 2026
19Vanguard Portfolio Management LLC986,459-101,308 (-9.31%)0.82%$3 MNov 13, 2026
20Hills Bank & Trust Co872,2000 (0.00%)0.72%$2 MNov 10, 2026
21Charles Schwab Investment Management Inc830,938+57,676 (+7.46%)0.69%$2 MNov 16, 2026
22Northern Trust Corp781,210-10,564 (-1.33%)0.65%$2 MNov 16, 2026
23Goldman Sachs Group Inc736,671-996,407 (-57.49%)0.61%$2 MNov 16, 2026
24Morgan Stanley624,200-1,288,350 (-67.36%)0.52%$2 MNov 13, 2026
25Vanguard Fiduciary Trust Co603,036+14,033 (+2.38%)0.50%$2 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Perspective Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Voya Investment Management LLC453,650+116,149 (+34.41%)0.38%$1 MNov 10, 2026
27Royal Bank Of Canada437,033+429,408 (+5631.58%)0.36%$1 MNov 16, 2026
28WealthPlan Investment Management, LLC404,0710 (0.00%)0.33%$1 MOct 15, 2026
29Bank Of America Corp /de/373,360-92,094 (-19.79%)0.31%$1 MNov 16, 2026
30Wellington Management Group LLP370,782+303,337 (+449.75%)0.31%$1 MNov 16, 2026
31Nuveen, LLC359,265+22,448 (+6.66%)0.30%$1 MNov 10, 2026
32Bank of New York Mellon Corp307,636+9,914 (+3.33%)0.25%$1 MNov 5, 2026
33Seven Fleet Capital Management LP296,087-36,526 (-10.98%)0.25%$1 MNov 16, 2026
34Gsa Capital Partners LLP295,419+1,637 (+0.56%)0.24%$1 MNov 16, 2026
35FMR LLC268,001-59,252 (-18.11%)0.22%$1 MNov 10, 2026
36Federated Hermes, Inc.227,112+10,089 (+4.65%)0.19%$1 MNov 12, 2026
37Renaissance Technologies LLC221,633+162,500 (+274.80%)0.18%$1 MNov 12, 2026
38BNP Paribas Financial Markets220,280+99,391 (+82.22%)0.18%$1 MNov 12, 2026
39Citigroup Inc214,791-120,126 (-35.87%)0.18%$1 MNov 4, 2026
40XTX Topco Ltd185,404+153,804 (+486.72%)0.15%$1 MNov 16, 2026
41Ally Bridge Group (NY) LLC163,634-580,324 (-78.00%)0.14%$0 MNov 16, 2026
42American Century Companies Inc147,277+26,229 (+21.67%)0.12%$0 MNov 12, 2026
43Rhumbline Advisers135,118+11,819 (+9.59%)0.11%$0 MNov 10, 2026
44Bridgeway Capital Management, LLC133,694+72,894 (+119.89%)0.11%$0 MNov 16, 2026
45Barclays PLC127,023+104,976 (+476.15%)0.11%$0 MNov 6, 2026
46Jpmorgan Chase & Co126,416+79,278 (+168.18%)0.10%$0 MNov 12, 2026
47Empowered Funds, LLC122,894New0.10%$0 MNov 13, 2026
48Alliancebernstein L.P.109,380-10,650 (-8.87%)0.09%$0 MNov 16, 2026
49Trueblood Wealth Management, LLC99,7400 (0.00%)0.08%$0 MOct 23, 2026
50Deutsche Bank AG\88,126-12,631 (-12.54%)0.07%$0 MNov 6, 2026
51Taylor & Morgan Wealth Management, LLC86,000+20,000 (+30.30%)0.07%$0 MOct 9, 2026
52Price T Rowe Associates Inc /MD/85,9300 (0.00%)0.07%$0 MNov 16, 2026
53Susquehanna International Group, LLP85,368+55,579 (+186.58%)0.07%$0 MNov 16, 2026
54Panagora Asset Management Inc80,023New0.07%$0 MNov 12, 2026
55State Of Wisconsin Investment Board71,867-109,995 (-60.48%)0.06%$0 MNov 16, 2026
56Brevan Howard Capital Management LP69,292+55,566 (+404.82%)0.06%$0 MNov 16, 2026
57Creative Planning64,526+17,645 (+37.64%)0.05%$0 MNov 2, 2026
58Russell Investments Group, Ltd.61,012+21,150 (+53.06%)0.05%$0 MNov 6, 2026
59MetLife Investment Management, LLC60,290-1,065 (-1.74%)0.05%$0 MNov 16, 2026
60Aigen Investment Management, LP54,551+34,042 (+165.99%)0.05%$0 MNov 16, 2026
61Perkins Capital Management Inc51,200+33,000 (+181.32%)0.04%$0 MNov 2, 2026
62MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.50,105-10,487 (-17.31%)0.04%$0 MNov 16, 2026
63HRT Financial LP49,219New0.04%$0 MNov 13, 2026
64Invesco Ltd.49,092-3,774 (-7.14%)0.04%$0 MNov 12, 2026
65Sykon Capital LLC37,9320 (0.00%)0.03%$0 MNov 16, 2026
66Auctus Advisors LLC37,359+17,015 (+83.64%)0.03%$0 MOct 23, 2026
67Vanguard Global Advisers, LLC37,022+533 (+1.46%)0.03%$0 MNov 13, 2026
68Police & Firemen's Retirement System of New Jersey35,082-638 (-1.79%)0.03%$0 MNov 9, 2026
69Tudor Investment Corp Et Al33,714+15,608 (+86.20%)0.03%$0 MNov 16, 2026
70HSBC Holdings PLC33,549+14,339 (+74.64%)0.03%$0 MNov 16, 2026
71Schonfeld Strategic Advisors LLC28,746New0.02%$0 MNov 16, 2026
72Manufacturers Life Insurance Company, The28,345+13 (+0.05%)0.02%$0 MNov 13, 2026
73WINTON GROUP Ltd26,600New0.02%$0 MNov 12, 2026
74Koa Wealth Management, LLC25,9750 (0.00%)0.02%$0 MOct 14, 2026
75Natixis24,382+18,086 (+287.26%)0.02%$0 MNov 6, 2026
76Moneta Group Investment Advisors LLC23,7070 (0.00%)0.02%$0 MNov 13, 2026
77Wells Fargo & Company/mn22,081-64,409 (-74.47%)0.02%$0 MNov 16, 2026
78Vontobel Holding Ltd.22,0000 (0.00%)0.02%$0 MOct 16, 2026
79Point72 Asset Management, L.P.21,260New0.02%$0 MNov 16, 2026
80Mercer Global Advisors Inc /adv20,893-1,225 (-5.54%)0.02%$0 MNov 16, 2026
81Mariner, LLC19,832New0.02%$0 MNov 12, 2026
82Iowa State Bank19,0610 (0.00%)0.02%$0 MOct 6, 2026
83Simplex Trading, LLC17,360-16,580 (-48.85%)0.01%$0 MNov 4, 2026
84Prudential Financial Inc16,6100 (0.00%)0.01%$0 MNov 16, 2026
85Provenance Wealth Advisors, LLC16,000New0.01%$0 MOct 30, 2026
86HighTower Advisors, LLC15,625-174 (-1.10%)0.01%$0 MNov 10, 2026
87Wealth Effects LLC15,000-20,000 (-57.14%)0.01%$0 MOct 23, 2026
88ProShare Advisors LLC12,968-554 (-4.10%)0.01%$0 MOct 29, 2026
89Caitong International Asset Management Co., Ltd12,084+10,744 (+801.79%)0.01%$0 MOct 29, 2026
90Jump Financial, LLC11,841-49,359 (-80.65%)0.01%$0 MNov 13, 2026
91Global Retirement Partners, LLC10,757+7,777 (+260.97%)0.01%$0 MNov 10, 2026
92Victory Capital Management Inc10,537+109 (+1.05%)0.01%$0 MNov 10, 2026
93Aquatic Capital Management LLC10,406New0.01%$0 MNov 16, 2026
94New York State Common Retirement Fund10,3000 (0.00%)0.01%$0 MNov 17, 2026
95CIBC Bancorp USA Inc.10,210New0.01%$0 MNov 13, 2026
96Cetera Investment Advisers10,1920 (0.00%)0.01%$0 MNov 13, 2026
97Equitable Holdings, Inc.10,060+60 (+0.60%)0.01%$0 MNov 16, 2026
98Two Sigma Securities, LLC10,033New0.01%$0 MNov 16, 2026
99Legal & General Group Plc10,0290 (0.00%)0.01%$0 MNov 16, 2026
100Ameritas Investment Partners, Inc.9,3720 (0.00%)0.01%$0 MNov 13, 2026

All 118 institutional investors, with who bought and sold →

Mutual funds holding Perspective Therapeutics, Inc.#

103 funds hold shares worth $69 M (about 16.8% of the company). Since their previous reports 75 added shares and 13 sold, buying $21 M net.
Mutual funds holding Perspective Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.4.04 M$14 M3.3%0.13%+136%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.31 M$11 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.65 M$9 M2.2%0.01%+76%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.02 M$3 M0.84%<0.01%+6.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors977,879$3 M0.81%0.02%+84%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.13 M$3 M0.93%<0.01%+83%Jul 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors636,237$2 M0.53%0.02%−8.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC445,775$2 M0.37%<0.01%+17%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.405,058$2 M0.34%<0.01%+39%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.319,770$1 M0.26%<0.01%+8.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors346,808$1 M0.29%0.08%+122%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.288,380$1 M0.24%<0.01%−0.8%May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC258,600$1 M0.21%0.02%no changeMay 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP269,566$1 M0.22%<0.01%+147%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP254,330$1 M0.21%<0.01%−31%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.251,300$1 M0.21%<0.01%+90%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP237,159$1 M0.20%<0.01%+87%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC168,934$1 M0.14%<0.01%+35%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC193,052$1 M0.16%0.01%+106%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC193,329$1 M0.16%<0.01%no changeJul 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series188,576$1 M0.16%0.07%no changeJul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.136,400$1 M0.11%0.03%newMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC129,409$1 M0.11%<0.01%+48%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC144,625$0 M0.12%0.02%+87%Jun 30, 2026
🇺🇸 Voya MI Dynamic Small Cap FundVoya Investments, LLC105,819$0 M0.09%0.22%newMay 31, 2026
🇺🇸 Voya Small Company PortfolioVoya Investments, LLC117,819$0 M0.10%0.18%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC137,405$0 M0.11%<0.01%+91%Jul 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC137,152$0 M0.11%0.08%+37%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC112,058$0 M0.09%0.01%+88%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust87,725$0 M0.07%0.01%+565%May 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP95,830$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation75,600$0 M0.06%0.01%+80%Jun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.63,522$0 M0.05%<0.01%+1.5%May 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC73,326$0 M0.06%0.03%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC61,780$0 M0.05%0.01%+42%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.57,911$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.47,669$0 M0.04%0.01%+9.8%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.53,460$0 M0.04%0.01%+100%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC53,010$0 M0.04%<0.01%+53%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors52,405$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC50,000$0 M0.04%0.12%−50%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.47,732$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.53,471$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC49,345$0 M0.04%<0.01%+89%Jul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP48,875$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC44,085$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC30,917$0 M0.03%0.07%—Apr 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC34,788$0 M0.03%0.01%+73%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company27,964$0 M0.02%<0.01%+22%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC29,450$0 M0.02%0.01%+87%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC28,184$0 M0.02%<0.01%+49%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC28,063$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.27,500$0 M0.02%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC30,537$0 M0.03%<0.01%+2.7%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC23,054$0 M0.02%0.04%+106%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS22,706$0 M0.02%0.01%+92%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC21,601$0 M0.02%0.01%+90%Jun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC19,647$0 M0.02%0.04%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC21,124$0 M0.02%<0.01%+172%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC17,994$0 M0.01%<0.01%+42%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.16,195$0 M0.01%0.01%+89%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC16,118$0 M0.01%0.01%+72%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.15,751$0 M0.01%0.01%+98%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors14,823$0 M0.01%<0.01%−0.7%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC13,881$0 M0.01%0.01%+68%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds13,847$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP16,052$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC12,538$0 M0.01%0.01%+93%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC12,410$0 M0.01%<0.01%+25%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC13,727$0 M0.01%<0.01%+6.5%Jul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP13,021$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.10,674$0 M<0.01%<0.01%−32%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC12,094$0 M0.01%<0.01%+72%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management9,372$0 M<0.01%0.01%+71%Jun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC8,968$0 M<0.01%0.02%+79%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION7,700$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.10,428$0 M<0.01%<0.01%−1.3%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC8,258$0 M<0.01%0.01%+67%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS9,096$0 M<0.01%<0.01%+87%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC7,389$0 M<0.01%0.01%+95%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC6,207$0 M<0.01%<0.01%+61%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC7,299$0 M<0.01%<0.01%+209%Jul 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.5,998$0 M<0.01%<0.01%−7.9%Jun 30, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP6,000$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC5,035$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC5,013$0 M<0.01%<0.01%+77%Jun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC4,720$0 M<0.01%<0.01%+21%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,954$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP5,300$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS5,020$0 M<0.01%<0.01%+548%Jul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,626$0 M<0.01%<0.01%+152%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,925$0 M<0.01%<0.01%+13%May 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC3,920$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,312$0 M<0.01%<0.01%−37%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,288$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,607$0 M<0.01%<0.01%+77%Jun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC2,136$0 M<0.01%<0.01%−5.0%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,850$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC2,096$0 M<0.01%<0.01%+21%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,903$0 M<0.01%<0.01%+40%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Perspective Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$163 K
9 purchases, 5 insiders
Sold, 12 months
$1.3 M
7 sales, 2 insiders
Net, 12 months
-$1.1 M
open market only
Insiders on file
23
since
$57.4 M-$1.0 M$0Dec 2023: bought $279 K (9 trades), sold $0 (0 trades)Dec 23Jan 2024: bought $335 K (15 trades), sold $0 (0 trades)Mar 2024: bought $57.4 M (1 trades), sold $0 (0 trades)MarMay 2024: bought $151 K (5 trades), sold $0 (0 trades)Jun 2024: bought $235 K (5 trades), sold $0 (0 trades)JunNov 2024: bought $172 K (9 trades), sold $0 (0 trades)Dec 2024: bought $130 K (2 trades), sold $0 (0 trades)DecMar 2025: bought $317 K (6 trades), sold $0 (0 trades)Nov 2025: bought $42 K (2 trades), sold $0 (0 trades)NovAug 2026: bought $0 (0 trades), sold $245 K (2 trades)Sep 2026: bought $0 (0 trades), sold $1.0 M (5 trades)SepNov 2026: bought $163 K (9 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Perspective Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Robert F. Williamson IIIDirectorBuyindirect+25,000$0.838$21 K53,473Form 4
filed Frank MorichDirectorBuy+15,000$0.936$14 K30,000Form 4
filed Robert F. Williamson IIIDirectorBuyindirect+18,609$0.840$16 K28,473Form 4
filed Lori A. WoodsDirectorBuy+23,750$0.844$20 K28,557Form 4
filed Frank MorichDirectorBuy+15,000$0.997$15 K15,000Form 4
filed Robert F. Williamson IIIDirectorBuy+6,289$0.839$5 K115,271Form 4
filed Markus PuhlmannChief Medical OfficerBuy+35,000$0.845$30 K178,542Form 4
filed Markus PuhlmannChief Medical OfficerBuy+6,000$0.830$5 K143,542Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Perspective Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
9.0 M
12.1% of shares · 2.47 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split

Trading halts

  • 2026-10-23 12:12 UTC, code T3, resumed 15:05 UTC
  • 2024-11-21 14:43 UTC, code M, resumed 14:48 UTC

Fails to deliver

  • : 31,425 shares at $1.17
  • : 59,588 shares at $1.19
  • : 56,853 shares at $1.21
  • : 28,959 shares at $2.26
  • : 106 shares at $2.19

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Perspective Therapeutics, Inc. scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-67.4%Free cash flow is -67.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.40 vs -1.23Diluted EPS -1.40 in fiscal 2025 against -1.23 the year before (report's currency).
    • ✗Net income higher than five years earlier-$103 M-$103 M in fiscal 2025 against -$3 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$103 MNet income -$103 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-41.4%-41.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 4
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.17 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.01 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $29 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year14.6%Diluted shares up 14.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Perspective Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Perspective Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017FY 2016to Jun 30, 2016
Income statement
Revenue——1.411109.77.35.94.84.8r
Cost of revenue———6.24.94.64.34.13.94.6r
Gross profit——1.40r5.15.13.01.80.80.1r
Research and development8442210.9r1.41.11.51.71.00.5r
Selling and marketing———2.82.43.02.72.72.31.4r
General and administrative3027215.6r4.74.64.24.23.9r3.8r
Operating expenses11492426.4r8.68.68.38.67.15.2r
Operating income−114−91−41−6.4r−3.4−3.5−5.3−6.7−6.3−5.1r
Interest and finance income8.1110.90.10.10.00.10.00.10.2r
Interest expense and finance costs——0.10————00.0r
Share of profit of associates−0.0−0.0−0.00——————
Other non-operating income (expense)9.1100.80.10.10.00.10.00.10.4r
Income before tax−104−80−40−6.3——————
Income tax−0.8−2.1−2.70000000
Income from discontinued operations—0.2————————
Net income attributable to shareholders−103−79−47−7.3−3.4−3.4−5.1−6.7−6.2−4.7r
Earnings per share, basic-1.40-1.23-1.74r-0.05-0.03-0.05-0.08-0.12-0.11-0.09
Earnings per share, diluted-1.40-1.23-1.74—-0.03-0.05-0.08-0.12-0.11-0.09
Shares, weighted average (basic)746427r14210468————
Shares, weighted average (diluted)746427—1046867555555r
Balance sheet
Cash and cash equivalents31629.256642.45.32.6r5.910r
Short-term investments11416500———0.83.02.2r
Receivables0.00.11.21.62.02.01.21.20.70.6r
Inventory———1.41.00.60.50.50.30.3r
Other current assets0.00.1r0.0r0.00.0r0.0r0.0r0.0r0.0r0.0r
Current assets1482311759675.57.35.41014r
Property, plant and equipment77575.62.02.01.71.61.31.10.6r
Right-of-use (leased) assets1.52.20.70.50.81.0————
Goodwill—024———————
Other intangible assets0.40.30.40.10.10.10.20.20.20.2r
Investments in associates0.10.10.1———————
Long-term investments————————03.0r
Total assets2673419864708.79.47.51218r
Accounts payable21106.9r1.00.70.70.71.40.60.6r
Current liabilities2918162.31.81.61.11.81.11.1r
Lease liabilities (non-current)1.01.40.80.30.50.8————
Total liabilities6050233.23.03.01.72.41.71.7r
Retained earnings−335−232−152−99−91−88−84−79−73−66r
Shareholders' equity2072917561675.77.75.01116r
Total liabilities and equity267341986470—9.47.51218r
Shares outstanding747128r1421426967565555
Cash-flow statement
Depreciation and amortization3.32.31.0—————0.10.5r
Share-based compensation9.05.43.71.10.40.50.40.40.40.3r
Cash from operating activities−82−18−37−7.7−2.8−3.6−5.0−5.7−5.7−3.9
Capital expenditure−13−54−1.1−0.3−0.4−0.3−0.4−0.3−0.5−0.5r
Intangible assets bought——−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0r
Cash from investing activities41−21924−0.3−0.4−0.30.41.91.58.8r
Shares issued—2760.40———0.5—0
Cash from financing activities102890.80.1651.07.40.5−0.00.0r
Change in cash−3152−12−7.961−2.92.7−3.3−4.24.9r
Report10-K10-K10-K/A10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Perspective Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.4 M
Johan (Thijs) Spoor
Other top executives, average
$1.8 M
the CEO earned 1.4× this
$100 invested is now
$110
Perspective Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Johan (Thijs) Spoor$2.4 M$2.2 M$1.8 M$110
2024Chief executive$5.4 M$2.2 M$1.8 M$128
2023Chief executive$1.5 M$1.8 M$1.0 M$160

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Perspective Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 1 · Shareholder vote 1 · Results announced 9

Perspective Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Perspective Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$87 MPrivate placement after listing$50 to $250 million9equitySEC
Jan 2024$21 MPrivate placement after listing$10 to $50 million1equitySEC
Feb 2023$55 MPrivate placement after listing$50 to $250 million54equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Perspective Therapeutics, Inc.#

$68 K spent on lobbying the US Congress and federal agencies in 2024, most often on health issues.

Lobbying, 2024
$68 K
#1,204 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2024
2026 so far
—
  • Health Issues3 reports

Lobbying firms hired in 2024

FOLEY HOAG LLP $68 K

Perspective Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2024$68 K—3
2023$90 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Perspective Therapeutics, Inc. fka IsoRay Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Perspective Therapeutics, Inc.#

4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $128 K a year.

Certified, FY2026
4
#1,252 among companies on value.today
Worker positions
4
Median wage offered
$128 K
a year, full-time
Applications filed
4
Perspective Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Research ScientistMedical Scientists, Except Epidemiologists2$98 K
Chief Business Strategy OfficerGeneral and Operations Managers1$362 K
Senior Clinical Data ManagerClinical Data Managers1$158 K

Where: Coralville, IA 3 · Springfield, MO 1

Perspective Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202644$128 K4
FY202544$125 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Perspective Therapeutics, Inc.

How Perspective Therapeutics, Inc. compares in Biotechnology

  • Market cap$141 M · higher than 40% of 726
  • Price / book0.7× · lower than 86% of 534
  • FCF yield-67.4% · higher than 18% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Perspective Therapeutics, Inc.🇺🇸$141 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Perspective Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Perspective Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Perspective Therapeutics, Inc.? Suggest a correction